Reality not insanity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Reality not insanity
CDMOs waiting for the pipeline to come roaring back are kidding themselves.


Pharmaceutical Technology Europe
Volume 21, Issue 11

Coming to terms

The contract services industry needs to come to terms with the fact that the new product gravy train is coming to an end. The number of candidates in development is shrinking and the amount spent on them is falling. R&D spending by small bio/pharma companies dropped 20% in the first half of 2009 and the large and midsize companies have also slowed their spending. We may get an upturn in the second half of the year as some delayed programmes are accelerated, but the trend seems pretty clear.

A decline in R&D spending will hurt smaller CROs and CMOs the most because it will be concentrated in the discovery, preclinical and Phase I segments of the pipeline. Those are the segments of the pipeline that will feel the greatest effects of the venture capital pullback, and the venture-backed bio/pharmas are the most dependent on contractors.

Large public CROs and CMOs will also feel the heat. Their stock prices were driven up to record levels during the middecade, as high doubledigit revenue and profit growth rates became the norm. Those growth rates have slowed dramatically and aren't likely to reach their pre2008 levels. The Phase II and Phase III research programmes have been well supported thus far, but the efforts to kill likely failures more quickly will ultimately shrink the latestage pipeline.

Contract services will benefit from the increased willingness of the major bio/pharma companies to outsource more of their development activities. However, much of that benefit will accrue to large CROs and CMOs, and to service providers with operations in the emerging markets. Owners and investors of contract service providers must come to terms with this new reality. The venture capitalists and executives of the major bio/pharma companies are not insane; they have already turned away from the practices that fuelled the great pipeline explosion this decade. CROs and CMOs will now need to find other ways to fuel their growth.

Jim Miller is President of PharmSource and a member of Pharmaceutical Technology Europe's Editorial Advisory Board.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here